C73 - Multiple Sclerosis Therapy: Disease-modifying Treatment II
| Event Time: | Sunday May 5, 2019 3:30 pm to 5:30 pm |
| Topic(s): | MS and CNS Inflammatory Disease, Foundations in Clinical Neurology for APPs |
| Director(s): | John Rose MD, FAAN |
| Description: | The use of disease-modifying treatments (DMTs) in MS is one of the most rapidly evolving therapeutic areas in neurology. As new and arguably more effective treatments have become available, decision-making in regard to MS DMTs has become much more complex for both neurologists and people with MS. This course will review the mechanisms of action and the risk-benefit ratios of the DMTs and delve into different treatment paradigms, risk mitigation strategies, sequencing considerations, and shared decision making. This program complements Multiple Sclerosis Therapy: Disease-modifying Treatment I, but covers independent topics. |
| Completion Message: | Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge, Practice-Based Learning and Improvement |
| Start/End Time | Title | Faculty |
|---|---|---|
| 3:30 PM - 4:00 PM | Treatment of Pediatric MS | Emmanuelle Waubant MD, PhD, FAAN |
| 4:00 PM - 4:30 PM | Treatment of Progressive MS | Maria K. Houtchens MD |
| 4:30 PM - 5:00 PM | Future Directions for MS DMTs | Emmanuelle Waubant MD, PhD, FAAN |
| 5:00 PM - 5:30 PM | Future of Remyelination in MS | Maria K. Houtchens MD |
| Speaker | Disclosure |
|---|---|
| Maria K. Houtchens, MD | Dr. Houtchens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme Sanofi, Teva Neurosciences, Biogen, Genentech. Dr. Houtchens has received research support from Genzyme Sanofi, Biogen, Serono. |
| Emmanuelle Waubant, MD, PhD, FAAN | Dr. Waubant has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AAN for Frontiers in neurology talk, The Corpus for talks, compensation for editorial work for Annals of Clinical and Translational Neurology and MS and Related Disorders. Site PI for clinical trials with Roche, Biogen Idec and Novartis |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |